WASHINGTON & COLUMBUS, OHIO, April 28, 2026
Paradigm Health has announced a landmark research collaboration with the U.S. Food and Drug Administration (FDA) to develop a next-generation real-time regulatory review model for clinical trial data. This initiative, already operational in Phase 2 and Phase 1b clinical trials, leverages Paradigm Health’s technology-enabled Study Conduct platform to enable continuous data capture, automated analysis, and near real-time reporting of safety and efficacy signals. The collaboration aims to transform traditional clinical trial workflows, significantly reducing data processing timelines from months to days, while enhancing regulatory efficiency, patient safety monitoring, and trial cost optimization.
Real-Time Data Platform Transforms Clinical Trial Execution
At the core of the initiative is Paradigm Health’s AI-powered Study Conduct platform, which integrates data directly from electronic health records (EHRs) and other structured and unstructured sources. The system is designed to automatically evaluate FDA-defined endpoints and critical data points, transmitting only the most relevant regulatory signals to sponsors and the FDA.
This approach minimizes the need for manual data entry, redundant monitoring, and bulk data transfers, enabling a more streamlined, scalable, and efficient clinical trial infrastructure. Importantly, the platform ensures that all transmitted data remains traceable, auditable, and compliant with patient privacy standards, aligning with stringent GxP and regulatory compliance frameworks. By enabling continuous visibility into trial performance, the model introduces a paradigm shift toward adaptive and responsive clinical development processes.
Industry Collaboration Accelerates Innovation
Advertisement
Leading pharmaceutical companies, including Amgen and AstraZeneca, are among the first to adopt this innovative model. The collaboration has already been implemented in an AstraZeneca-sponsored Phase 2 trial conducted at premier research institutions such as MD Anderson Cancer Center and Perelman School of Medicine, as well as an Amgen-sponsored Phase 1b trial.
These early deployments demonstrate the platform’s ability to integrate seamlessly into complex clinical environments, supporting real-time regulatory engagement and faster decision-making. The initiative reflects a broader industry shift toward digitally enabled, data-driven clinical research, where collaboration between regulators, sponsors, and technology providers is essential for accelerating therapeutic innovation.
Building the Future of Regulatory Science and Drug Development
The collaboration directly supports the FDA’s strategic vision of transitioning toward a continuous, real-time regulatory review environment, addressing long-standing challenges associated with lengthy, costly, and complex clinical trials. By reducing operational inefficiencies and enabling faster regulatory feedback loops, the model has the potential to accelerate the development and approval of life-saving therapies, ultimately benefiting patients worldwide.
From a GxP perspective, the initiative reinforces adherence to Good Clinical Practice (GCP) and data integrity standards, while introducing advanced digital infrastructure to modernize regulatory workflows. Furthermore, the scalable nature of the platform could make the United States a more competitive hub for clinical research, attracting innovation and investment in the life sciences sector.
As the demand for efficient and patient-centric clinical trials continues to grow, Paradigm Health’s collaboration with the FDA represents a transformational step toward a more agile, transparent, and technology-driven future in drug development, with the potential to redefine how clinical data is generated, analyzed, and reviewed across the global healthcare ecosystem.
Source: Paradigm Health press release
